Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,784 total articles

Hanmi Reports 2026 First Quarter Results

Hanmi Reports 2026 First Quarter Results

Hanmi Financial Corporation reported a 6.2% increase in net income to $22.6 million for Q1 2026 compared to Q4 2025, driven by loan growth, net interest margin expansion, and stable expenses. The bank improved asset quality, with nonperforming assets down 38%, and further strengthened its capital position. Deposit growth and diversification of the …

Orrstown Financial Services, Inc. Reports First Quarter 2026 Results

Orrstown Financial Services, Inc. Reports First Quarter 2026 Results

Orrstown Financial Services, Inc., parent company of Orrstown Bank, announced first quarter 2026 results showing net income of $21.8 million and diluted EPS of $1.12, both slightly up from the previous quarter. The company reported strong loan growth, increased deposits, improved capital ratios, and reduced noninterest expenses. The bank maintained…

Scorpio Tankers Inc. Announces that on May 5, 2026, the Company Plans to Issue Its First Quarter 2026 Results and Have a Conference Call

Scorpio Tankers Inc. Announces that on May 5, 2026, the Company Plans to Issue Its First Quarter 2026 Results and Have a Conference Call

Scorpio Tankers Inc., a provider of marine transportation of petroleum products, announced it will release its first quarter 2026 financial results on May 5, 2026, followed by a conference call to discuss the results. The company currently owns 87 product tankers and has several newbuildings and sales of vessels planned between 2026 and 2029. The a…

Perimeter Announces Date for First Quarter 2026 Earnings Call

Perimeter Announces Date for First Quarter 2026 Earnings Call

Perimeter Solutions announced that it will release its first quarter 2026 financial results on May 6, 2026, prior to market open. The company will host a conference call the same day to discuss the results, led by CEO Haitham Khouri, CFO Kyle Sable, and Head of Investor Relations Seth Barker. The company operates in two main segments: Fire Safety a…

Getty Realty Corp. Announces Regular Quarterly Cash Dividend

Getty Realty Corp. Announces Regular Quarterly Cash Dividend

Getty Realty Corp., a net lease REIT specializing in convenience and automotive retail real estate, announced a cash dividend of $0.485 per common share payable July 9, 2026, to shareholders of record as of June 25, 2026. The company’s portfolio comprises 1,174 properties across 44 U.S. states and Washington, D.C.

Bank OZK Announces First Quarter 2026 Earnings

Bank OZK Announces First Quarter 2026 Earnings

Bank OZK announced its first quarter 2026 financial results, reporting net income available to common stockholders of $159.3 million, a 5.1% decrease year-over-year, and diluted earnings per share of $1.44, down 2.0%. The bank highlighted its strong management and strategic positioning to navigate ongoing macroeconomic and geopolitical challenges.

Interparfums, Inc. Reports 2026 First Quarter Net Sales

Interparfums, Inc. Reports 2026 First Quarter Net Sales

Interparfums, Inc. reported a 2% increase in consolidated net sales for Q1 2026 to $345 million, driven by solid performances in select brands and favorable foreign exchange rates. Organic sales declined by 2% when adjusted for the Middle East conflict. Key growth brands included Coach and Montblanc, while Lacoste and overall Jimmy Choo sales decli…

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Immuneering announced it will present updated survival data from a Phase 2a clinical trial evaluating the combination of atebimetinib and modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. The expanded cohort includes 55 patients, highlighting the drug's mechanism designed to improve survival by durable tumor shrin…

American Coastal Insurance Corporation  Schedules First Quarter Financial Results and Conference Call

American Coastal Insurance Corporation Schedules First Quarter Financial Results and Conference Call

American Coastal Insurance Corporation, a Florida-based insurance holding company specializing in insuring condominium and homeowner association properties, plans to release its Q1 2026 financial results on May 5, 2026. The company will hold a conference call immediately after, providing remarks and a Q&A session to discuss the quarter's performanc…

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Holding AG has published its invitation to the 2026 Annual General Meeting scheduled for May 13, 2026, in Zug, Switzerland, including details for in-person attendance and webcast access. Additionally, the company will host a shareholder information session on May 11, focusing on meeting proposals and company updates. Oculis continues to adva…

AvePoint to Announce First Quarter 2026 Financial Results on May 7

AvePoint to Announce First Quarter 2026 Financial Results on May 7

AvePoint, a leader in AI data protection and governance, announced it will report its Q1 2026 financial results on May 7, 2026, followed by a conference call to discuss financial performance and business trends. The company provides unified data security and resilience solutions across multiple cloud platforms, serving over 28,000 customers globall…

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics presented new preclinical data demonstrating the efficacy and safety of its innovative drug candidates targeting chromatin regulatory proteins involved in cancer. The lead compound, selective SMARCA2 inhibitor FHD-909, in combination with an anti-PD-1 antibody, showed complete and durable tumor regression and immune memory in m…